Erik van den Berg, CEO of Memo Therapeutics, shares his insights about leadership in biopharma and how Memo is working to develop antibodies to transform the lives of patients with viral infections and cancer.
Erik van den Berg, CEO of Memo Therapeutics, shares his insights about leadership in biopharma and how Memo is working to develop antibodies to transform the lives of patients with viral infections and cancer.
